Sarepta Therapeutics Inc. (SRPT) Upgraded to “Outperform” at William Blair
William Blair upgraded shares of Sarepta Therapeutics Inc. (NASDAQ:SRPT) from a market perform rating to an outperform rating in a research note issued to investors on Monday. They currently have $88.00 price target on the stock.
A number of other research analysts also recently weighed in on SRPT. Vetr downgraded shares of Sarepta Therapeutics from a hold rating to a sell rating and set a $17.28 target price for the company. in a research report on Monday, May 23rd. Wedbush reaffirmed a neutral rating and issued a $14.00 target price on shares of Sarepta Therapeutics in a research report on Wednesday, May 25th. Oppenheimer Holdings Inc. reaffirmed an outperform rating and issued a $60.00 target price on shares of Sarepta Therapeutics in a research report on Thursday, May 26th. Robert W. Baird reaffirmed an outperform rating and issued a $23.00 target price on shares of Sarepta Therapeutics in a research report on Thursday, May 26th. Finally, Royal Bank Of Canada reaffirmed a sector perform rating and issued a $5.00 target price on shares of Sarepta Therapeutics in a research report on Thursday, May 26th. One investment analyst has rated the stock with a sell rating, five have given a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of Buy and an average target price of $48.70.
Sarepta Therapeutics (NASDAQ:SRPT) opened at 60.97 on Monday. The firm has a 50-day moving average price of $30.01 and a 200-day moving average price of $21.91. Sarepta Therapeutics has a 52 week low of $8.00 and a 52 week high of $61.60. The firm’s market capitalization is $2.92 billion.
Sarepta Therapeutics (NASDAQ:SRPT) last released its earnings results on Tuesday, July 19th. The company reported ($1.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.19) by $0.16. During the same quarter last year, the company earned ($0.87) EPS. Equities analysts forecast that Sarepta Therapeutics will post ($4.17) EPS for the current year.
In related news, CEO Edward M. Md Kaye sold 24,557 shares of Sarepta Therapeutics stock in a transaction that occurred on Wednesday, September 14th. The shares were sold at an average price of $30.00, for a total transaction of $736,710.00. Following the sale, the chief executive officer now directly owns 76,983 shares of the company’s stock, valued at approximately $2,309,490. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP David T. Howton sold 9,304 shares of Sarepta Therapeutics stock in a transaction that occurred on Monday, September 19th. The shares were sold at an average price of $50.00, for a total transaction of $465,200.00. Following the sale, the senior vice president now directly owns 11,168 shares in the company, valued at $558,400. The disclosure for this sale can be found here. Corporate insiders own 10.90% of the company’s stock.
Several large investors have recently made changes to their positions in SRPT. American Century Companies Inc. acquired a new stake in Sarepta Therapeutics during the second quarter worth $651,000. Eagle Asset Management Inc. acquired a new stake in Sarepta Therapeutics during the second quarter worth $6,756,000. Amici Capital LLC acquired a new stake in Sarepta Therapeutics during the first quarter worth $488,000. LGL Partners LLC raised its stake in Sarepta Therapeutics by 4.2% in the first quarter. LGL Partners LLC now owns 24,862 shares of the company’s stock worth $485,000 after buying an additional 1,000 shares during the last quarter. Finally, A.R.T. Advisors LLC acquired a new stake in Sarepta Therapeutics during the first quarter worth $7,461,000. 72.09% of the stock is currently owned by institutional investors.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.
Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.